High-fat diet and glucocorticoid treatment cause hyperglycemia associated with adiponectin receptor alterations by Cristiane de Oliveira et al.
RESEARCH Open Access
High-fat diet and glucocorticoid treatment
cause hyperglycemia associated with adiponectin
receptor alterations
Cristiane de Oliveira, Ana BM de Mattos, Carolina Biz, Lila M Oyama, Eliane B Ribeiro,
Cláudia Maria Oller do Nascimento*
Abstract
Background: Adiponectin is the most abundant plasma protein synthesized for the most part in adipose tissue, and
it is an insulin-sensitive hormone, playing a central role in glucose and lipid metabolism. In addition, it increases fatty
acid oxidation in the muscle and potentiates insulin inhibition of hepatic gluconeogenesis. Two adiponectin
receptors have been identified: AdipoR1 is the major receptor expressed in skeletal muscle, whereas AdipoR2 is
mainly expressed in liver. Consumption of high levels of dietary fat is thought to be a major factor in the promotion
of obesity and insulin resistance. Excessive levels of cortisol are characterized by the symptoms of abdominal obesity,
hypertension, glucose intolerance or diabetes and dyslipidemia; of note, all of these features are shared by the
condition of insulin resistance. Although it has been shown that glucocorticoids inhibit adiponectin expression in
vitro and in vivo, little is known about the regulation of adiponectin receptors. The link between glucocorticoids and
insulin resistance may involve the adiponectin receptors and adrenalectomy might play a role not only in regulate
expression and secretion of adiponectin, as well regulate the respective receptors in several tissues.
Results: Feeding of a high-fat diet increased serum glucose levels and decreased adiponectin and adipoR2 mRNA
expression in subcutaneous and retroperitoneal adipose tissues, respectively. Moreover, it increased both adipoR1
and adipoR2 mRNA levels in muscle and adipoR2 protein levels in liver. Adrenalectomy combined with the synthetic
glucocorticoid dexamethasone treatment resulted in increased glucose and insulin levels, decreased serum
adiponectin levels, reduced adiponectin mRNA in epididymal adipose tissue, reduction of adipoR2 mRNA by 7-fold in
muscle and reduced adipoR1 and adipoR2 protein levels in muscle. Adrenalectomy alone increased adiponectin
mRNA expression 3-fold in subcutaneous adipose tissue and reduced adipoR2 mRNA expression 2-fold in liver.
Conclusion: Hyperglycemia as a result of a high-fat diet is associated with an increase in the expression of the
adiponectin receptors in muscle. An excess of glucocorticoids, rather than their absence, increase glucose and
insulin and decrease adiponectin levels.
Background
Adiponectin, the most abundant plasma protein that is
synthesized from differentiated adipocytes, has reduced
plasma levels in clinical conditions associated with insu-
lin resistance, including obesity, type 2 diabetes, dyslipi-
demia and hypertension [1,2]. Furthermore, adiponectin
levels are inversely associated with visceral adiposity [3].
Several studies have demonstrated that adiponectin has
a central role in glucose and lipid metabolism. Accord-
ingly, the infusion of adiponectin in mice decreased the
expression of hepatic gluconeogenesis enzymes, inhibited
glucose production and increased the hepatic effect of
insulin [4]. In addition to its effect on glucose levels, adi-
ponectin improved insulin sensitivity by reducing the
levels of free fatty acids in the plasma and by increasing
their oxidation in the muscle, according to some authors
[5,6]. Moreover, adiponectin has been reported to exhibit
anti-atherosclerotic and anti-inflammatory effects [7,8].* Correspondence: Claudia.oller@unifesp.br
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Two adiponectin receptors have been identified: adi-
poR1 is the major receptor expressed in skeletal muscle,
whereas adipoR2 is mainly expressed in liver [9-11].
These receptors are also expressed in adipose tissue
(with adipoR1 being expressed 10 to15-fold higher than
adipoR2), macrophages and pancreatic beta cells [11-13].
A study by Rasmussen et al [13] found that weight loss
caused upregulation of the gene expression of the adipo-
nectin receptors in human adipose tissue. Additionally, it
has been demonstrated that there is a weight loss-
induced improvement in insulin sensitivity that could be
mediated by the upregulation of adiponectin [14].
It has been previously demonstrated that saturated fatty
acids increase insulin resistance and the incidence of car-
diovascular disease and that monounsaturated fatty acids
(MUFA) and polyunsaturated fatty acids (PUFA) are pro-
tective against the development of these diseases [15,16].
Few studies have investigated the effect of diet composi-
tion on the expression of adiponectin and its receptors.
One such study showed that that a high calorie diet
decreased serum adiponectin levels [17]. Bullen et al [18]
showed that age and a high-fat diet, both of which predis-
pose an organism to obesity and insulin resistance,
reduced adiponectin and increased adipoR1 and adipoR2
levels. Furthermore, Mullen et al [19] found that 3 days
of feeding a diet high in saturated fat induced adiponec-
tin resistance in the soleus muscle of rats; this was not
observed when the rats were treated with a diet high in
PUFA. Thus, the authors concluded that the type of fatty
acids in the diet is a critical factor in the development of
adiponectin resistance.
We have previously demonstrated that feeding a diet
rich in saturated fat and PUFA for 2 days resulted in
decreased serum adiponectin concentrations and adipo-
nectin gene expression in the retroperitoneal adipose tis-
sue of mice. Similar results were observed after 8 weeks
of a PUFA-rich diet treatment only [20]. Additionally, the
8-week treatment with a PUFA-rich diet increased the
corticosterone plasma concentrations in rats [21].
An excess of cortisol, as seen in Cushing’s syndrome or
with clinical administration of glucocorticoids that is
used to treat acute and chronic inflammatory diseases,
leads to symptoms of abdominal obesity, hypertension,
glucose intolerance or diabetes and dyslipidemia, all of
which are also features of insulin resistance [22-24]. The
decrease of glucocorticoids with an adrenalectomy can
reverse hyperglycemia in many models of obesity [25-27]
and can increase insulin sensitivity in obese mice [28].
Previous studies have shown that glucocorticoids inhi-
bit adiponectin expression in vitro and in animal models
[29-32] and that adrenalectomy can stimulate adiponec-
tin expression in the white adipose tissue of ob/ob mice
[33]. However, few studies have analyzed the effects of
glucocorticoids on the expression of adiponectin
receptors, and the results of these studies have been
controversial. In hepatocytes, dexamethasone stimulated
the adipoR2 promoter, and this effect was abolished by
the glucocorticoid receptor antagonist RU486 [34]. In
contrast, dexamethasone decreased adipoR2 mRNA
expression in human skeletal muscle [32].
The aims of the present study were to investigate the
effects of a high-fat diet on adiponectin receptor expres-
sion and to determine the effects of adrenalectomy and
dexamethasone treatment in rats treated with a high-fat
diet on the expression levels of adiponectin and adipo-
nectin receptors in adipose tissue, skeletal muscle and
liver.
Materials and methods
Animals and diets
Eight-week-old male Wistar rats were obtained from the
Universidade Federal de São Paulo, Centro de Desenvol-
vimento de Modelos Experimentais (CEDEME) and
housed under controlled conditions with a 12-h light/
dark cycle (lights on at 6 am) at 22 ± 1°C in the animal
room of the Division of Nutrition Physiology with free
access to food and water. All animal procedures were
conducted in accordance with the guidelines for the
care and use of laboratory animals and were approved
by the Committee on Animal Research Ethics of the
Federal University of São Paulo (Process n° 01201-6).
At 9 weeks of age, rats were fed a normal chow diet
(C; 5% fat) or a high-fat diet (HF; control diet enriched
with 15% soybean oil) for 21 days.
The HF diet was prepared in the Laboratory of Nutri-
tion Physiology using the commercial chow Nuvilab
CR1 (Paraná, Brazil) with casein added to obtain a final
20% protein content and enrichment with 15% (w/w) of
commercial soybean oil (Liza, Brazil) and 0.013% buty-
lated hydroxytoluene (w/w). Water was added to obtain
the consistency necessary to allow homogenization of
the mixture. After homogenization, the mixture was
passed through a milling machine to produce pellets
that were then dried in a forced ventilation oven at 60°C
for 24 h. The prepared pellets were stored in plastic
containers at 4°C.
The HF diet used in this study contained 19.4 g lipid/
100 g and 379.0 Kcal/100 g, whereas the control diet
contained 3.0 g lipid/100 g and 280.6 Kcal/100 g. The
protein content was similar in both diets (± 21.8 g pro-
tein/100 g). The fatty acid composition of the diets mea-
sured as a percentage of the total lipid content was
previously described [20].
Surgery and experimental procedures
At 12 weeks of age, rats were anesthetized using a mix-
ture of ketamine and xylosine (66.6 and 13.3 mg/Kg,
respectively) administered by intraperitoneal injection
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and then they underwent complete bilateral adrenal
gland removal via dorsal incision. Subsequently, rats
received dexamethasone reposition (A-DEXA; 0.2 mg/
100 g body weight (BW) twice per day) by subcutaneous
injections or not (ADREC). A total dosage of 0.4 mg per
100 g BW per day was used to guarantee treatment with
a supra-physiological dose. Sham adrenalectomized rats
(S-ADREC) underwent a similar surgery without removal
of the adrenal glands and received subcutaneous injection
of 0.9% saline solution twice daily. Saline solution was
provided as an additional fluid to adrenalectomized rats.
The animals were sacrificed by decapitation without
sedation 72 h after surgery. Retroperitoneal (RET), epidi-
dymal (EPI) and subcutaneous (SUB) adipose tissues, as
well as the gastrocnemius muscle (MUSC) and liver were
collected, frozen in liquid nitrogen and stored at -80°C
for RNA and protein extraction. Trunk blood was col-
lected and immediately centrifuged; the resulting serum
was stored at -80°C until the measurement of serum
glucose, insulin, corticosterone and adiponectin
concentrations.
Biochemical and hormonal serum analysis
Commercial ELISA kits were used to measure the serum
levels of adiponectin (ALPCO and AdipoGen) and insulin
(LINCO and Millipore). Blood glucose levels were deter-
mined using the Glucose PAP Liquiform kit (Labtest)
and serum corticosterone was assayed by Enzyme Immu-
noassay (EIA) (Cayman Chemical Co).
Carcass lipid and protein contents
Carcasses were eviscerated, weighed, and stored at -20°C.
The lipid content was measured [35] and standardized
[36] as previously described. Briefly, the eviscerated car-
casses were autoclaved at 120°C for 90 min and homoge-
nized with a double body weight of water. Aliquots of
this homogenate were taken in triplicate, weighed and
digested in 3 ml 30% KOH and 3 ml ethanol for at least 2
h at 70°C in capped tubes. After cooling, 2.5 ml 6N
H2SO4 was added, and the samples were washed 3 times
with petroleum ether for lipid extraction. Results are
expressed as grams of lipid per 100 g of carcass. For pro-
tein measurements, aliquots of the same homogenate
(weighing approximately 1 g) were heated to 37°C for 1 h
in 0.6 N KOH with constant shaking. After clarification
by centrifugation, protein content was measured accord-
ing to a previously described method [37].
RNA extraction and complementary DNA synthesis
Total RNA was isolated from adipose tissue, muscle and
liver samples using TRIzol (Invitrogen) according to the
manufacturer’s recommendations. The concentrations of
RNA samples were determined by measuring the absor-
bance at 260 nm. The purity of the RNA samples was
determined by calculating the absorbance ratios between
260 and 280 nm and by electrophoresis using an ethi-
dium bromide-stained gel. For reverse transcription,
1 μg of total RNA was reverse transcribed using an M-
MLV reverse transcriptase kit (Promega) and the follow-
ing reaction conditions: 65°C for 10 min, 37°C for
60 min and 65°C for 10 min.
Real-time PCR
The relative levels of adiponectin, adipoR1 and adipoR2
mRNAs were measured in duplicate by real-time PCR
using SYBR green dye and an ABI Prism 7300 sequence
detection system (Applied Biosystems, USA). Reactions
were incubated as follows: an initial denaturation step at
95°C for 10 min followed by 40 cycles of 95°C for 15 s
and 60°C for 1 min and culminating with melt curve ana-
lysis. All results were normalized to the values of the
housekeeping gene hypoxanthine phosphoribosyltransfer-
ase (HPRT) and expressed as the fold change relative to
the control group using the 2-ΔΔCt method [38]. The
following rat primer sets were used: adiponectin forward,
5’-AATCCTGCCCAGTCATGAAG, and reverse, 5’-CAT
CTCCTGGGTCACCCTTA; adipoR1 forward, 5’-CTT
CTACTGCTCCCCACAGC, and reverse, 5’-TCCCAGG
AACACTCCTGCTC; adipoR2 forward, 5’-ATGTTTGC-
CACCCCTCAGTA, and reverse, 5 ’-CAGATGTCA-
CATTTGGCAGG; and HPRT forward, 5’-CTCATGGA
CTGATTATGGACAGGAC, and reverse, 5’-GCAGG
TCAGCAAAGAACTTATAGCC.
Protein analysis by western blotting
Samples of each collected tissue (0.05-0.3 g) were homo-
genized in 1.0 mL extraction buffer (100 mM Trizma,
pH 7.5, 10 mM EDTA, 1% SDS, 10 mM sodium pyro-
phosphate, 100 mM sodium fluoride, 10 mM sodium
orthovanadate, 2 mM PMSF and 0.25 mg aprotinin pro-
tease inhibitor). The lysates were incubated with 10%
Triton X-100 for 30 min and then centrifuged at 14,000
rpm for 30 min at 4°C. The supernatant was collected,
and protein concentration was determined using a Brad-
ford assay (Bio-Rad, Hercules, California) using bovine
serum albumin (BSA) as a reference standard.
The protein samples were treated with Laemmli sam-
ple buffer and boiled for 5 min before loading 30-60 μg
protein onto a 12% SDS-PAGE gel in a Bio-Rad minia-
ture slab gel apparatus. Electrotransfer of the proteins
from the gel to a nitrocellulose membrane was per-
formed for 1 h at 120 V (constant voltage) using a
Bio-Rad miniature transfer apparatus. Nonspecific pro-
tein binding to the nitrocellulose was reduced by a 2-h
preincubation in blocking buffer (1% BSA, 10 mM Tris,
150 mM NaCl and 0.02% Tween 20). The nitrocellulose
membranes were incubated overnight at 4°C with anti-
bodies against adipoR1, adipoR2 (both 1:1,000; Santa
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Cruz Biotechnology, CA, USA) or a-tubulin (1:3,000;
Santa Cruz) that were diluted in blocking buffer com-
bined with 1% bovine agarose and then washed for 30
min in blocking buffer without BSA. The membranes
were then incubated with secondary antibody, either
anti-goat for adipoR1 and adipoR2 (1:10,000) or anti-
mouse for a-tubulin (1:5,000), from Santa Cruz Biotech-
nology. The blots were subsequently incubated with a
peroxidase-conjugated secondary antibody for 1 h at
22°C, processed for enhanced chemiluminescence
(Amersham ECL Detection Reagent, GE Healthcare) to
visualize the immunoreactive bands and developed using
Hybond ECL Nitrocellulose membrane (Amersham, GE
Healthcare). The protein bands were identified accord-
ing to their migration rate in comparison to the rainbow
recombinant protein molecular weight markers and
quantified by densitometry using Image J software.
Results are expressed as arbitrary units relative to
a-tubulin.
Statistical analysis
Data are presented as the mean ± SEM. An unpaired
Student’s t-test was used to assess potential differences
between the C and HF diet groups. A one-way ANOVA
followed by the Tukey post hoc test were used to com-
pare the results between surgical groups (S-ADREC,
ADREC and A-DEXA). Differences were considered to
be significant when p < 0.05.
Results
1. The effects of the PUFA-rich diet
The daily energy intakes were similar between the C and
HF groups over the 21 days of treatment. The body
weight gain of these groups was also similar, with no
significant difference in body weight at the end of the
feeding experiment (336.60 ± 7.27 g vs. 353.28 ± 5.49 g
for the C and HF groups, respectively, p = 0.08). In
addition, no significant differences were observed in car-
cass protein or lipid content or concentrations of serum
corticosterone, insulin or adiponectin between the C
and HF groups. However, HF diet caused an increase in
serum glucose concentrations compared to the control
diet (152.16 ± 13.33 vs. 97.72 ± 16.12 mg/dL for HF and
C groups, respectively, p < 0.01) (Table 1).
Analysis of adiponectin gene expression in various adi-
pose tissue depots showed 4-fold decreased expression
in the SUB depot (p < 0.005) of the HF group, but no
change in expression in the RET or EPI depots com-
pared to the control group (Figure 1). AdipoR2 gene
expression was 4-fold lower in the RET adipose tissue of
the HF group compared to the control group (p < 0.05),
whereas there was no change in adipoR2 protein con-
tent. We did not find any significant alterations in the
mRNA or protein levels in the EPI or SUB adipose tis-
sue depots (Figure 2).
We observed a tissue-specific effect of HF diet on adi-
poR1 and adipoR2 expression (Figure 3): hepatic adi-
poR2 gene expression was increased approximately
2-fold (p ≤ 0.05), whereas there was no significant effect
on adipoR1 expression and no alteration in the protein
levels of either receptor. In the muscle, only adipoR2
gene expression was significantly increased (7-fold
increase in HF group compared to controls, p < 0.05);
in contrast, there was no significant effect on adipoR1
gene expression, but there was a slight increase in adi-
poR1 protein expression (67%).
2. The effects of corticosterone
As expected, removal of the adrenal glands resulted in
reduced serum corticosterone levels. Adrenalectomy did
not change glucose or insulin levels. However, in the
group that was adrenalectomized and that received dexa-
methasone treatment (A-DEXA), the serum levels of glu-
cose and insulin were significantly higher than in the
sham adrenalectomized (S-ADREC) or adrenalectomized
(ADREC) groups (glucose: 310.70 ± 31.70, 152.16 ±13.33
and 144.08 ± 21.25 mg/dL in the A-DEXA, S-ADREC
and ADREC groups, respectively; insulin: 5.10 ± 0.81 vs.
1.83 ± 0.10 vs. 1.55 ± 0.37 ng/mL in the A-DEXA,
S-ADREC and ADREC groups, respectively). In addition,
serum adiponectin levels did not change in the ADREC
group, but the A-DEXA group exhibited decreased adipo-
nectin levels (7.01 ± 0.56, 12.62 ± 1.21 and 10.50 ±
1.9 μg/mL in the A-DEXA, S-ADREC and ADREC
groups, respectively), showing that an excess of glucocor-
ticoids affects glucose, insulin and adiponectin levels,
whereas absence of glucocorticoids does not (Table 2).
The adrenalectomy (ADREC) induced a 4-fold
increase in adiponectin gene expression of the SUB adi-
pose tissue depot compared to the sham adrenalecto-
mized (S-ADREC) group, but there was no change in
that of the RET or EPI depots. In contrast, the A-DEXA
Table 1 Effects of 21 days of chow diet and high-fat diet
C group HF group
Body weight gain (g) 82.53 ± 6.7 (15) 77.32 ± 3.51 (25)
Daily energy intake (Kj) 5764,72 (15) 5642,22 (25)
Carcass protein (g/100 g) 41.61 ± 2.44 (8) 42.31 ± 2.42 (7)
Carcass lipid (g/100 g) 10.07 ± 0.58 (12) 11.77 ± 1.08 (10)
Corticosterone (μg/dL) 0.637 ± 0.22 (6) 0.526 ± 0.19 (6)
Glucose (mg/dL) 97.72 ± 16.12 (8) 152.16 ±13.33 * (6)
Insulin (ng/mL) 1.72 ± 0.27 (8) 1.83 ± 0.10 (7)
Adiponectin (μg/mL) 10.42 ± 1.07 (6) 12.62 ± 1.21 (7)
HF: high fat diet. Results presented as the mean ± SEM. A Student’s t-test was
used for statistical comparisons between the HF and control (C) groups;
p < 0.05.
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Figure 1 Effect of a high-fat (HF) diet on adiponectin gene expression in (A) retroperitoneal (RET), (B) epididymal (EPI) and
(C) subcutaneous (SUB) adipose tissue. Fold change data are expressed as the mean ± SEM. Values were normalized to HPRT gene
expression with n = 5-9 per group. A Student’s t-test was used for statistical comparisons between the HF and control (C) groups; *p < 0.005.
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Figure 2 Effect of a high-fat diet (HF) on the mRNA and protein expression of the adiponectin receptors adipoR1 and adipoR2 in
(A) retroperitoneal (RET), (B) epididymal (EPI) and (C) subcutaneous adipose tissue (SUB). Data are expressed as the mean ± SEM.
mRNA values were normalized to HPRT, and protein values were normalized to a-tubulin with n = 5-9 per group. A Student’s t-test was
used for statistical comparisons between the HF and control (C) groups; *p < 0.05.
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group had a 3.5-fold decrease in the mRNA abundance
of adiponectin in the EPI adipose tissue compared to
the ADREC group (Figure 4).
We did not find any significant alterations in the
mRNA levels of adipoR1 and adipoR2 in any adipose
tissue depots analyzed; however, in the SUB adipose tis-
sue of the ADREC group, the protein expression levels
of adipoR1 and adipoR2 were higher than the S-ADREC
or A-DEXA groups. In the EPI adipose tissue, the A-
DEXA group had 66% less adipoR1 protein than the S-
ADREC group (Figure 5). In the gastrocnemius muscle,
the dexamethasone therapy (A-DEXA) group had a 7-
fold reduction in the expression of the adipoR2 gene,
and no changes were observed in adipoR1 mRNA abun-
dance between groups. The protein expression levels of
both adipoR1 and adipoR2 were reduced (55% and 65%,
respectively) in the A-DEXA group compared to the S-
ADREC group; a similar finding was observed with pro-
tein expression of adipoR2 in muscle (Figure 6).
Adrenalectomy reduced hepatic adipoR2 gene expres-
sion approximately 2-fold, whereas it did not affect adi-
poR1 gene expression or alter protein levels of either
receptor (Figure 6).
Discussion
The present study evaluated the effects of a high-fat diet on
the expression of adiponectin and adiponectin receptors in
rats. These rats did not become obese during the study
because the percentage of fat in their diet and the period
of diet treatment were not great enough to alter the body
A                AdipoR1   - 42 kDa 
                AdipoR2   - 44 kDa 
      
                          AdipoR1  - 42 kDa 
B                   AdipoR2  - 44 kDa
* 
* 
** 
     C                 HF   
     C               HF     
Figure 3 Effect of a high-fat diet (HF) on the mRNA and protein expression of the adiponectin receptors adipoR1 and adipoR2 in
(A) liver and (B) muscle. Data are expressed as the mean ± SEM. Values were normalized to HPRT with n = 5-9 per group. A Student’s t-test
was used for statistical comparisons between the HF and control (C) groups; *p < 0.05.
Table 2 Effects of adrenalectomy and dexamethasone
treatment in rats treated with high-fat diet
HF group
n S-ADREC ADREC A-DEXA
Corticosterone (μg/
dL)
5-6 0.526 ± 0.19 0.013 ± 0.01a 0.018 ± 0.01a
Glucose (mg/dL) 5-6 152.16
±13.33
144.08 ±
21.25
310.70 ±
31.70ab
Insulin (ng/mL) 6-7 1.83 ± 0.10 1.55 ± 0.37 5.10 ± 0.81ab
Adiponectin (μg/
mL)
6-7 12.62 ± 1.21 10.50 ± 1.91 7.01 ± 0.56a
Results presented as the mean ± SEM. A one-way ANOVA followed by a Tukey
post-hoc test was used to determine significant differences between groups;
*p < 0.05 (effect due to surgery); a ≠ S-ADREC; b ≠ ADREC. Shaw
adrenalectomy (S-ADREC), Adrenalectomized group (ADREC), adrenalectomy
with dexamethasone treatment (A-DEXA; 0.2 mg/100 g, twice per day).
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Figure 4 Effects of adrenalectomy (ADREC) and adrenalectomy with dexamethasone treatment (A-DEXA; 0.2 mg/100 g, twice per day)
on adiponectin gene expression in (A) retroperitoneal (RET), (B) epididymal (EPI) and (C) subcutaneous (SUB) adipose tissue in rats
treated with HF diet. Data are expressed as the mean ± SEM. Values were normalized to HPRT levels with n = 5-9 per group. A one-way
ANOVA followed by a Tukey post-hoc test was used to determine significant differences between groups (*p < 0.05, effect due to surgery).
S-ADREC, sham adrenalectomy.
de Oliveira et al. Lipids in Health and Disease 2011, 10:11
http://www.lipidworld.com/content/10/1/11
Page 8 of 14
A              AdipoR1  - 42 kDa
               AdipoR2  - 44 kDa 
      
    
B              AdipoR1  - 42 kDa
               AdipoR2  - 44 kDa 
      
 
C               AdipoR1   - 42 kDa
               AdipoR2   - 44 kDa
      
*
* ** * *
S-ADREC  ADREC  A-DEXA   
S-ADREC  ADREC  A-DEXA   
S-ADREC  ADREC  A-DEXA   
Figure 5 Effects of adrenalectomy (ADREC) and adrenalectomy with dexamethasone treatment (A-DEXA; 0.2 mg/100 g, twice per day)
on the gene and protein expression of the adiponectin receptors adipoR1 and adipoR2 in (A) retroperitoneal (RET), (B) epididymal
(EPI) and (C) subcutaneous (SUB) adipose tissue in rats treated with high-fat (HF) diet. Data are expressed as the mean ± SEM. mRNA
values were normalized to HPRT, and protein values were normalized to a-tubulin with n = 5-9 per group. A one-way ANOVA followed by a
Tukey post-hoc test was used to determine significant differences between groups (*p < 0.05, **p < 0.01, effect due to surgery). S-ADREC, sham
adrenalectomy.
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weight gain or the carcass lipid content compared to the
group fed normal chow. Therefore, we can be sure that
our results were restricted to the effects of the diet and
were not due to metabolism changes induced by obesity.
Some studies show that adiponectin plays a role in the
reduction of insulin sensitivity caused by high-fat diet
[39,40]. Our results showed that 21 days of a high-fat
diet containing 20% fat was not enough to modify insu-
lin serum concentrations although there was an increase
in glycemia. We demonstrated that hyperglycemia pro-
moted by the high-fat diet was accompanied by a reduc-
tion in adiponectin gene expression in the SUB adipose
tissue, but did not lead to a decrease in serum adiponec-
tin levels, suggesting that there is a compensatory effect
of the other fat depots on serum adiponectin levels.
These results demonstrate the complexity of post-tran-
scriptional mechanisms regulating adiponectin mRNA.
The isolated effect of the high-fat diet on the SUB adi-
pose tissue may be due to the fact that adiponectin gene
and protein levels are higher in SUB adipose tissue than
in other adipose depots [41,42].
Previous studies have suggested that increased insulin
levels due to a high-fat diet may affect expression of the
adiponectin receptors [18,43,44]. This insulin regulatory
effect on adiponectin receptor expression is controver-
sial because it has been shown that insulin represses the
expression of both adiponectin receptors in muscle and
liver [43], that adipoR1, but not adipoR2, is repressed by
insulin [45], that there is no difference in adipoR1
expression in the muscles of human diabetics compared
to non-diabetics [46,47] and, similar to our results, that
insulin increases adipoR1 expression in muscle [48,49].
In our study, we also demonstrated that there was a
decrease in adipoR1 protein expression in the RET adi-
pose tissue. However, because the insulin levels in our
HF group and C group were similar, we can assume
that the alterations in the expression of adiponectin
receptors were not due to insulin. Free fatty acid levels
A                 AdipoR1   - 42 kDa 
                                                                                                                                        AdipoR2   - 44 kDa 
      
B               AdipoR1   - 42 kDa 
                 AdipoR2   - 44 kDa 
* 
* ** 
** 
*** 
S-ADREC     ADREC       A-DEXA      
S-ADREC     ADREC       A-DEXA      
Figure 6 Effects of adrenalectomy (ADREC) and adrenalectomy with dexamethasone treatment (A-DEXA; 0.2 mg/100 g, twice per day)
on gene expression of the adiponectin receptors adipoR1 and adipoR2 gene in (A) muscle and (B) liver. Data are expressed as the mean
± SEM. Values were normalized to HPRT with n = 5-9 per group. A one-way ANOVA followed by a Tukey post-hoc test was used to determine
significant differences between groups (*p < 0.05, **p < 0.01, ***p < 0.005, effect due to surgery). S-ADREC, sham adrenalectomy.
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have also been found to upregulate adiponectin receptor
expression [46].
Some previous studies have shown that diet-induced
obesity is associated with insulin resistance in liver and
muscle, but not in adipose tissue [50,51]. However, in
the present study, we demonstrated that adipoR1 pro-
tein expression increased in muscle and adipoR2 gene
expression increased in muscle and liver after 3 weeks
of HF diet, suggesting that this may be a compensatory
mechanism that acts to protect an organism from insu-
lin resistance induced by HF diet because it has been
well documented that adiponectin expression in muscle
promotes an increase in insulin sensitivity [52,53]. Simi-
lar results were found in a study by Barnea et al [49] in
which HF diet enhanced adipoR1 and adipoR2 expres-
sion in the muscles of mice fed with a 22% soybean fat
diet for 4 months.
Peng et al [54] have proposed that adiponectin signal-
ing may be a crosslink between HF diet, hepatic inflam-
mation and nonalcoholic fatty liver disease. In fact, they
found that HF diet-induced liver steatosis was associated
with a reduction in serum adiponectin levels and down-
regulation of adipoR2 expression in the liver. We found
that adipoR2 gene expression was increased in the livers
of the HF group of rats. A similar result was found by
Bullen et al [18] in mice fed a high-fat diet. These
results indicate that other factors may play a role in the
regulation of the adiponectin receptors in the liver.
The stimulation of adrenal glucocorticoid secretion by
HF diet has been described in animals and humans
[55,56]. Accordingly, Wohlers et al [21] showed that
feeding rats for 7 weeks with a HF diet that was supple-
mented with soybean oil or fish oil (15% fat) resulted in
increased serum corticosterone levels compared to those
in rats fed a control diet (4% fat). Our animals fed with
a soybean oil HF diet (15% fat) for only 3 weeks did not
increase the serum levels of corticosterone compared to
those of the control group. After 3 weeks of HF diet
treatment, Drake et al [57] observed an increase in glu-
cocorticoid clearance by hepatic A-ring reductase. The
authors of this study suggested that this mechanism
could protect against the metabolic complications of
obesity induced by HF diet.
In HF diet-treated rats, 72 h after adrenalectomy, glyce-
mia and insulin levels were similar to the S-ADREC
group. However, glucocorticoid therapy via dexametha-
sone treatment in adrenalectomized rats promoted
hyperglycemia and hyperinsulinemia. This treatment also
decreased adiponectin serum concentrations, which was
accompanied by a decrease in adiponectin mRNA in EPI
adipose tissue, demonstrating that the excess of glucocor-
ticoids rather than the glucocorticoids themselves per se
influence adiponectin, glucose and insulin serum concen-
trations. Chronic treatment with glucocorticoids may
result in insulin resistance followed by hyperinsulinemia
and hyperglycemia [58-60]. These alterations of insulin
and glucose levels can be partially explained by a
decrease in insulin-dependent glucose uptake and an
increase in liver gluconeogenesis. Another potential
explanation could be the decrease in adiponectin serum
levels observed in the present study. Adrenalectomy may
increase adiponectin gene expression in SUB adipose tis-
sue even when combined with HF diet treatment because
HF diet alone was able to reduce adiponectin gene
expression. With regard to expression of the adiponectin
receptors in SUB adipose tissue, adrenalectomy increased
adipoR1 and adipoR2 protein levels, and the dexametha-
sone therapy reversed these effects. AdipoR2 protein
expression in muscle was reduced by adrenalectomy, but,
upon the addition of glucocorticoid therapy, the adipoR2
mRNA levels did not reach the normal mRNA levels
observed in the sham group. This reduction in adipoR2
expression may be due to other hormones secreted by
the adrenal glands, such as mineralocorticoids and cate-
cholamines, and, for this reason, the treatment with dex-
amethasone was not able to reverse the adipoR2
reduction. Furuhashi et al [61] observed that rennin-
angiotensin-aldosterone system blockade increases serum
adiponectin concentrations with improvement in insulin
sensitivity in patients with hypertension. To our knowl-
edge, no direct effects of aldosterone on adiponectin and
adiponectin receptors were observed despite the fact that
both adiponectin receptors, adipoR1 and adipoR2, have
been showed to be expressed in mouse adrenal gland and
adrenocortical Y-1 cells [62] and in human adrenal
cortex and aldosterone-producing adenoma tissue [63].
Few studies showed that exogenous administration of
dehydroepiandrosterone (DHEA) upregulated adiponec-
tin expression and secretion from adipose tissue of
rats [64,65]. Some studies have analyzed the effects of
catecholamines on the regulation of adiponectin and adi-
ponectin receptor gene and protein expression. Catecho-
lamines inhibit adiponectin mRNA expression in 3T3-L1
adipocytes [66] and adipoR1 and adipoR2 expression in
cultured cardiomyocytes [67]. In addition, Iwen et al [68]
recently showed that an increase in sympathetic nervous
activity caused a decrease in plasma adiponectin levels in
humans. Oana et al [10] showed that the b3-adrenocep-
tor agonist CL-316 increased plasma adiponectin levels
and the expression of adiponectin mRNA in the EPI
white adipose tissue of db/db mice. Another study by Fu
et al [69] demonstrated that treatment of 3T3-L1 adipo-
cytes with the b-adrenoceptor agonist isoproterenol
increased expression of the adipoR2, but not the adipoR1
receptor. These results are in accordance with the find-
ings of the present study related to the effects observed
in the A-DEXA group. However, more studies are needed
to better understand the effects of catecholamines on the
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regulation of the adiponectin system because some dis-
eases associated with obesity are related to sympathetic
nervous system activity.
Conclusion
Taken together, these results demonstrate that hypergly-
cemia due to a high-fat diet is associated with a decrease
in the expression of adiponectin receptors in the gastro-
cnemius muscle. Also, our results suggest that adrenalin
has a regulatory role in adipoR2 protein expression in
skeletal muscle.
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